Technical Analysis for CMRX - Chimerix, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.25% | |
| 50 DMA Resistance | Bearish | 0.25% | |
| 20 DMA Support | Bullish | 0.25% | |
| Fell Below 200 DMA | Bearish | -2.01% | |
| Fell Below 50 DMA | Bearish | -2.01% | |
| Upper Bollinger Band Walk | Strength | -2.01% | |
| Inside Day | Range Contraction | -2.01% | |
| Gapped Down | Weakness | -2.01% | |
| Crossed Above 200 DMA | Bullish | -6.68% | |
| Crossed Above 50 DMA | Bullish | -6.68% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 4 hours ago |
| Down 2 % | about 4 hours ago |
| Down 1% | about 4 hours ago |
| Up 1% | about 4 hours ago |
| 20 DMA Support | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 05/01/2024
Chimerix, Inc. Description
Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox. The company also develops CMX157, an oral nucleotide compound that is in Phase I clinical trials to treat HIV infections. It has a collaboration and license agreement with Merck, Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Viruses Virus Antiviral Drug Hematopoietic Stem Cell Herpes Papillomavirus Ebola Monkeypox Prodrugs Poxviruses Antivirals Cytomegalovirus Infection Orthopoxvirus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.57 |
| 52 Week Low | 0.88 |
| Average Volume | 334,293 |
| 200-Day Moving Average | 1.01 |
| 50-Day Moving Average | 1.01 |
| 20-Day Moving Average | 0.95 |
| 10-Day Moving Average | 0.99 |
| Average True Range | 0.06 |
| RSI (14) | 49.75 |
| ADX | 17.11 |
| +DI | 15.02 |
| -DI | 14.83 |
| Chandelier Exit (Long, 3 ATRs) | 0.87 |
| Chandelier Exit (Short, 3 ATRs) | 1.06 |
| Upper Bollinger Bands | 1.04 |
| Lower Bollinger Band | 0.87 |
| Percent B (%b) | 0.65 |
| BandWidth | 17.93 |
| MACD Line | 0.00 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0102 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.08 | ||||
| Resistance 3 (R3) | 1.08 | 1.05 | 1.06 | ||
| Resistance 2 (R2) | 1.05 | 1.02 | 1.05 | 1.05 | |
| Resistance 1 (R1) | 1.01 | 1.01 | 1.00 | 1.01 | 1.05 |
| Pivot Point | 0.98 | 0.98 | 0.97 | 0.98 | 0.98 |
| Support 1 (S1) | 0.95 | 0.96 | 0.93 | 0.95 | 0.91 |
| Support 2 (S2) | 0.92 | 0.94 | 0.92 | 0.90 | |
| Support 3 (S3) | 0.88 | 0.92 | 0.90 | ||
| Support 4 (S4) | 0.88 |
